Treatment With Intravenous Immune Globulin 10% In A Real-World Outpatient Setting

Intravenous immune globulin 10% liquid (IVIG 10%) is used in the treatment of primary immunodeficiency (PI). Originally approved in 2012 and then voluntarily withdrawn in 2016, IVIG 10% (BIVIGAM®) underwent manufacturing process improvements by a new manufacturer and was reintroduced to the US market in 2019. The purpose of this real-world study is to assess the tolerability of IVIG 10% infused in an outpatient setting.